Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting SHANGHAI, June 1, 2026 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code:… CISION PRNewswireJune 1, 2026
Carbice and Noctua Partner to Bring Advanced Thermal Pad Technology to DIY PC Builders Noctua is the exclusive retail distributor of Carbice® IP90 thermal pads for… CISION PRNewswireJune 1, 2026
Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment's Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema HANGZHOU, China, SHANGHAI and BOSTON, June 1, 2026 /PRNewswire/ — Lynk Pharmaceuticals… CISION PRNewswireJune 1, 2026
BusinessPress ReleaseMICROIP to Debut "AI Vehicle System Business Group" and Edge AI Innovations at COMPUTEX 2026 TAIPEI, June 1, 2026 /PRNewswire/ — MICROIP (TPEx: 7796), specializing in AI… CISION PRNewswireJune 1, 2026
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview TAIPEI, June 1, 2026 /PRNewswire/ — Jyong Biotech Ltd. (Nasdaq: MENS) (the… CISION PRNewswireJune 1, 2026
D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4… CISION PRNewswireJune 1, 2026
Press ReleaseImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO SUZHOU, China, June 1, 2026 /PRNewswire/ — ImmVira Group ("ImmVira") today announced… CISION PRNewswireJune 1, 2026
Press Release2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety… CISION PRNewswireJune 1, 2026
